Bladder cancer trial explores immunotherapy cocktails to fight recurrence

NCT ID NCT03317158

Ongoing Disease control Sponsor: Noah Hahn, M.D. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This phase 1/2 trial tests the immunotherapy drug durvalumab alone or combined with other treatments (BCG, radiation, or chemotherapy) in 55 people with non-muscle invasive bladder cancer. The goal is to find safe doses and see if these combinations can eliminate cancer and prevent it from coming back. Participants have different histories with BCG treatment, including those who did not respond or relapsed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (Imfinzi) with or without BCG, radiation, gemcitabine, or docetaxel
What this could lead to: If successful, this could point toward new combination treatments for bladder cancer that reduce recurrence and delay or avoid bladder removal.
What could go wrong: This is an early phase 1/2 trial with only 55 participants, so results may not apply broadly. Some combinations may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER UROTHELIAL CARCINOMA

Contacts and locations

Locations

BCG Oncology

Phoenix, Arizona, 85032, United States
Columbia University Irving Medical Center

New York, New York, 10032, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21231, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.